feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Active Biotech: Orphan Drug Designation for Tasquinimod in Myelofibrosis in the US
Redeye has a positive view of Active Biotech’s obtaining orphan drug status. We discuss the benefits in our comment.
RR
Richard Ramanius
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans